Tachykinin peptides

NeRRe Therapeutics raises £20 million in a Series B2 financing round

Retrieved on: 
Wednesday, July 7, 2021
Branches of biology, Neuropeptides, Neurotransmitters, Chronic cough, Cough, Tachykinin peptides, Idiopathic pulmonary fibrosis

Stevenage, UK, 7 July 2021 NeRRe Therapeutics, a clinical-stage company developing orvepitant, its wholly-owned neurokinin-1 (NK-1) antagonist, as a first in class treatment for disabling chronic cough caused by reflex hypersensitivity disorders, today announces it has raised an additional 20 million in a Series B2 financing round.

Key Points: 
  • Stevenage, UK, 7 July 2021 NeRRe Therapeutics, a clinical-stage company developing orvepitant, its wholly-owned neurokinin-1 (NK-1) antagonist, as a first in class treatment for disabling chronic cough caused by reflex hypersensitivity disorders, today announces it has raised an additional 20 million in a Series B2 financing round.
  • The proceeds from the financing round will primarily be used to fund the Phase 2 clinical development of orvepitant as a treatment for chronic cough associated with IPF.
  • NeRRe Therapeutics is a clinical-stage company developing orvepitant, a neurokinin(NK)-1 receptor antagonist, as a first in class, once daily breakthrough treatment for cough hypersensitivity disorders.
  • Fountain Healthcare Partners is a life science focused venture capital fund with EUR 300 million (USD 354 million) under management.

NeRRe Therapeutics raises £20 million in a Series B2 financing round

Retrieved on: 
Wednesday, July 7, 2021
Branches of biology, Neuropeptides, Neurotransmitters, Chronic cough, Cough, Tachykinin peptides, Idiopathic pulmonary fibrosis

Stevenage, UK, 7 July 2021 NeRRe Therapeutics, a clinical-stage company developing orvepitant, its wholly-owned neurokinin-1 (NK-1) antagonist, as a first in class treatment for disabling chronic cough caused by reflex hypersensitivity disorders, today announces it has raised an additional 20 million in a Series B2 financing round.

Key Points: 
  • Stevenage, UK, 7 July 2021 NeRRe Therapeutics, a clinical-stage company developing orvepitant, its wholly-owned neurokinin-1 (NK-1) antagonist, as a first in class treatment for disabling chronic cough caused by reflex hypersensitivity disorders, today announces it has raised an additional 20 million in a Series B2 financing round.
  • The proceeds from the financing round will primarily be used to fund the Phase 2 clinical development of orvepitant as a treatment for chronic cough associated with IPF.
  • NeRRe Therapeutics is a clinical-stage company developing orvepitant, a neurokinin(NK)-1 receptor antagonist, as a first in class, once daily breakthrough treatment for cough hypersensitivity disorders.
  • Fountain Healthcare Partners is a life science focused venture capital fund with EUR 300 million (USD 354 million) under management.

NT-814 by Bayer: A Non-Hormonal, Orally Administered, Potent and Selective Small Molecule Dual Antagonist of Neurokinin-1 and 3 receptors - Global Emerging Insight and Market Forecast to 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 10, 2021
Health, Pharmaceutical, Neuropeptides, Neurotransmitters, Branches of biology, Hot flash, Menopause, Tachykinin peptides

The "NT-814 - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "NT-814 - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • NT-814 is a non-hormonal, orally administered, potent and selective small molecule dual antagonist of both the neurokinin-1 and 3 receptors.
  • "NT-814 - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Vasomotor symptoms in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.